CAS 1009119-64-5
:Daclatasvir
Description:
Daclatasvir is an antiviral medication primarily used in the treatment of hepatitis C virus (HCV) infections. It functions as a direct-acting antiviral agent, specifically an NS5A inhibitor, which interferes with the viral replication process. Daclatasvir is characterized by its high potency against various HCV genotypes and is often used in combination with other antiviral drugs to enhance efficacy and reduce the risk of resistance. The substance is typically administered orally and has a favorable pharmacokinetic profile, allowing for once-daily dosing. Its chemical structure includes a complex arrangement of heterocycles, contributing to its mechanism of action and therapeutic effectiveness. Daclatasvir is generally well-tolerated, with a side effect profile that may include fatigue, headache, and nausea, though serious adverse effects are rare. As with any antiviral therapy, monitoring for drug interactions and adherence to treatment regimens is crucial for optimal outcomes in patients undergoing hepatitis C treatment.
Formula:C40H50N8O6
InChI:InChI=1S/C40H50N8O6/c1-23(2)33(45-39(51)53-5)37(49)47-19-7-9-31(47)35-41-21-29(43-35)27-15-11-25(12-16-27)26-13-17-28(18-14-26)30-22-42-36(44-30)32-10-8-20-48(32)38(50)34(24(3)4)46-40(52)54-6/h11-18,21-24,31-34H,7-10,19-20H2,1-6H3,(H,41,43)(H,42,44)(H,45,51)(H,46,52)/t31-,32-,33-,34-/m0/s1
InChI key:InChIKey=FKRSSPOQAMALKA-CUPIEXAXSA-N
SMILES:C([C@@H](NC(OC)=O)C(C)C)(=O)N1[C@@H](CCC1)C=2NC(=CN2)C3=CC=C(C=C3)C4=CC=C(C=C4)C=5NC(=NC5)[C@H]6N(C([C@@H](NC(OC)=O)C(C)C)=O)CCC6
Synonyms:- Carbamic acid, N,N'-[[1,1'-biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-, dimethyl ester
- Carbamic acid, N,N′-[[1,1′-biphenyl]-4,4′-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-, C,C′-dimethyl ester
- Daclatasvir
- Daclavirocyrl
- Daklanork
- Ebp 883
- Methyl [(2S)-1-{(2S)-2-[5-(4'-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-pyrrolidinyl]-1H-imidazol-5-yl}-4-biphenylyl)-1H-imidazol-2-yl]-1-pyrrolidinyl}-3-methyl-1-oxo-2-butanyl]c arbamate
- dimethyl (2S,2'S)-1,1'-((2S,2'S)-2,2'-(4,4'-(biphenyl-4,4'-diyl)bis(1H-imidazole-4,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl)dicarbamate
- BMS 790052
- Daclatasvir, >=98%
- Dimethyl ((2S,2'S)-((2S,2'S)-2,2'-(5,5'-([1,1'-biphenyl]-4,4'-diyl)bis(1H-imidazole-5,2-diyl))
- N,N'-[[1,1'-Biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]biscarbamic acid C,C'-dimethyl ester
- Daklinza
- Daclatasvir-d16
- diMethyl (2S,2'S)-1,1'-((2S,2'S)-2,2'-(4,4'-(biphenyl-4,4'-diyl)
- DiMethyl (2S, 2'S)-1, 1'-((2S, 2'S)-2, 2'-(4, 4'-(biphenyl-4, 4'-diyl)bis(1H-iMidazole-4, 2-diyl))bis(pyrrolidine-2, 1-diyl))bis(3-Methyl-1-oxobutane-2, 1-diyl)dicarbaMate (Related Reference)
- Dacaltasvir
- N,N'-[[1,1'-Biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]biscarbamic acid C,C'-dimethyl ester Daclatasvir BMS 790052
- BMS-790052(Daclatasvir)
- Dhaka He Wei
- Daclatasvir/EBP883
- See more synonyms
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 12 products.
Methyl ((S)-1-((S)-2-(5-(4'-(2-((S)-1-((Methoxycarbonyl)-L-Valyl)Pyrrolidin-2-Yl)-1H-Imidazol-5-Yl)-[1,1'-Biphenyl]-4-Yl)-1H-Imidazol-2-Yl)Pyrrolidin-1-Yl)-3-Methyl-1-Oxobutan-2-Yl)Carbamate
CAS:Methyl ((S)-1-((S)-2-(5-(4'-(2-((S)-1-((Methoxycarbonyl)-L-Valyl)Pyrrolidin-2-Yl)-1H-Imidazol-5-Yl)-[1,1'-Biphenyl]-4-Yl)-1H-Imidazol-2-Yl)Pyrrolidin-1-Yl)-3-Methyl-1-Oxobutan-2-Yl)CarbamateFormula:C40H50N8O6Purity:98%Molecular weight:738.88Carbamic acid, N,N'-[[1,1'-biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-, C,C'-dimethyl ester
CAS:Formula:C40H50N8O6Purity:98%Color and Shape:SolidMolecular weight:738.8750Daclatasvir
CAS:Daclatasvir (EBP 883/BMS-790052) is a potent HCV NS5A inhibitor with EC50 9-50 pM across various genotypes. Phase 3.Formula:C40H50N8O6Purity:99.81% - 99.99%Color and Shape:SolidMolecular weight:738.88Daclatasvir
CAS:Controlled ProductApplications Daclatasvir, inhibits the HCV protein NS5A, and thus can be used as a drug candidate for the treatment of hepatitis C (HCV).
References Gao, M., et al.: Nature, 465(7294), 96 (2010); Bell, T. W., Chem. Med. Chem., 5(10), 1663 (2010);Formula:C40H50N8O6Color and Shape:NeatMolecular weight:738.88Daclatasvir
CAS:Methyl ((S)-1-((S)-2-(5-(4'-(2-((S)-1-((methoxycarbonyl)-L-valyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)-[1,1'-biphenyl]-4-yl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamateFormula:C40H50N8O6Purity:98%Molecular weight:738.88Daclatasvir-d6
CAS:Controlled ProductFormula:C40D6H44N8O6Color and Shape:NeatMolecular weight:744.912Daclatasvir
CAS:Daclatasvir is a direct-acting antiviral agent, which is derived from synthetic chemical sources with a specific mode of action targeting the hepatitis C virus (HCV) replication process. It functions as an inhibitor of the HCV nonstructural protein 5A (NS5A), a vital component necessary for viral RNA replication and virion assembly. By binding to two distinct domains of NS5A, Daclatasvir disrupts its ability to function, thereby effectively halting the replication of the viral genome.
Formula:C40H50N8O6Purity:Min. 95%Molecular weight:738.88 g/mol
![Carbamic acid, N,N'-[[1,1'-biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(…](https://static.cymitquimica.com/products/IN/thumb/DA00036K.jpg)
